Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI

Blood

Volumn 122, Issue 24, 2013, Pages 3863-3870

  Copelan, Edward A ^a   Hamilton, Betty K ^b   Avalos, Belinda ^a   Ahn, Kwang W ^c   Bolwell, Brian J ^b   Zhu, Xiaochun ^c   Aljurf, Mahmoud ^d   Van Besien, Koen ^e   Bredeson, Christopher ^f   Cahn, Jean Yves ^g   Costa, Luciano J ^h   De Lima, Marcos ⁱ   Gale, Robert P ^j   Hale, Gregory A ^k   Halter, Joerg ^l   Hamadani, Mehdi ^m   Inamoto, Yoshihiro ⁿ   Kamble, Rammurti T ^o   Litzow, Mark R ^p   Loren, Alison W ^q   Marks, David I ^r   Olavarria, Eduardo ^s   Roy, Vivek ^t   Sabloff, Mitchell ^f   Savani, Bipin N ^u   Seftel, Matthew ^v   Schouten, Harry C ^w   Ustun, Celalettin ^x   Waller, Edmund K ^y   Weisdorf, Daniel J ^x   Wirk, Baldeep ^z   Horowitz, Mary M ^c   Arora, Mukta ^x   Szer, Jeff ^aa   Cortes, Jorge ^ab   Kalaycio, Matt E ^b   Maziarz, Richard T ^ac   Saber, Wael ^c   more..

^a LEVINE CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF OTTAWA   (Canada)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

^m WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

ⁿ USA   (United States)

^o CENTER FOR CELL AND GENE THERAPY   (United States)

^p MAYO CLINIC ROCHESTER   (United States)

^q UNIVERSITY OF PENNSYLVANIA   (United States)

^r BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^s Catherine Lewis Center   (Spain)

^t MAYO CLINIC   (United States)

^u VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^v UNIVERSITY OF MANITOBA   (Canada)

^w MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^x UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^y EMORY UNIVERSITY HOSPITAL   (United States)

^z UNIVERSITY OF FLORIDA   (United States)

^aa ROYAL MELBOURNE HOSPITAL   (Australia)

^ab UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ac OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA ANTIGEN; MYCOPHENOLIC ACID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL PNEUMONIA; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PATIENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD; UNRELATED DONORS; WHOLE BODY RADIATION; YOUNG ADULT;

EID: 84891072099     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-514448     Document Type: Article

References (49)

1. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977; 49(4):511-533.
2. Thomas ED, Buckner CD, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med. 1979; 301(11):597-599.
3. Thomas ED, Clift RA, Hersman J, et al. Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys. 1982;8(5):817-821.
4. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76(9):1867-1871.
5. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309(22): 1347-1353.
6. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70(5):1382-1388.
7. Copelan EA, Biggs JC, Thompson JM, et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood. 1991;78(3): 838-843.
8. Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood. 1992;79(10):2578-2582.
9. Ringd'en O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83(9): 2723-2730.
10. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994; 84(6):2036-2043.
11. Michel G, Gluckman E, Esperou-Bourdeau H, et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation-a report from the Socí et ́e Française de Greffe de Moelle. J Clin Oncol. 1994;12(6):1217-1222.
12. Devergie A, Blaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood. 1995;85(8):2263-2268.
13. Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant. 1998;22(5):439-443.
14. Ringd'en O, Remberger M, Ruutu T, et al Nordic Bone Marrow Transplantation Group. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood. 1999;93(7): 2196-2201.
15. Soci'e G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001; 98(13):3569-3574.
16. Litzow MR, P'erez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamidetotal body irradiation versus busulphancyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol. 2002;119(4):1115-1124.
17. Gupta V, Lazarus HM, Keating A. Myeloablative conditioning regimens for AML allografts: 30 years later. Bone Marrow Transplant. 2003;32(10): 969-978.
18. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16(1):31-42.
19. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89(8): 3055-3060.
20. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25(1):55-61.
21. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000;39(2):155-165.
22. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100(4): 1201-1207.
23. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood. 2003;102(1):31-35.
24. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (4 BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase 2 study. Biol Blood Marrow Transplant. 2002;8(3):145-154.
25. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8(9):493-500.
26. Sobecks RM, Rybicki L, Yurch M, et al. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS. Bone Marrow Transplant. 2012;47(5):633-638.
27. Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol. 2007;2(1):75-91.
28. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17): 1813-1826.
29. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22): 2091-2101.
30. Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of highdose busulphan in adults. Eur J Clin Pharmacol. 1989;36(5):525-530.
31. Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res. 1994;14(6A): 2363-2370.
32. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
33. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204-217.
34. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-4083.
35. Loberiza FR Jr, Zhang MJ, Lee SJ, et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood. 2005; 105(7):2979-2987.
36. Commenges D, Andersen PK. Score test of homogeneity for survival data. Lifetime Data Anal. 1995;1(2):145-156, discussion 157-159.
37. Lee E, Wei LJ, Amato D, Leurgans S. Cox-Type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein J, Goel P, eds. Survival Analysis: State of the Art. Columbus, Ohio: Springer Netherlands; 1992:237-247
38. Zhang X, Loberiza FR, Klein JP, Zhang MJ. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed. 2007;88(2):95-101.
39. Weisdorf D, Spellman S, Haagenson M, et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. 2008;14(7):748-758.
40. Hassan M, Ljungman P, Ringd'en O, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 2000;25(9):915-924.
41. Lindley C, Shea T, McCune J, et al. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. Anticancer Drugs. 2004;15(5):453-459.
42. Bredeson C, Le-Rademacher J, Zhu X, et al. Improved survival with intravenous busulfan (4 Bu) compared to total body irradiation (TBI)- Based Myeloablative conditioning regimens: A CIBMTR prospective study. Biol Blood Marrow Transplant. 2013;19(2):S110-S111.
43. Dunn CD. The chemical and biological properties of busulphan. Exp Hematol. 1974;2(3):101-117.
44. Down JD, Boudewijn A, Dillingh JH, Fox BW, Ploemacher RE. Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs. Br J Cancer. 1994;70(4): 611-616.
45. Abkowitz JL, Taboada M, Shelton GH, Catlin SN, Guttorp P, Kiklevich JV. An X chromosome gene regulates hematopoietic stem cell kinetics. Proc Natl Acad Sci USA. 1998;95(7):3862-3866.
46. Donahue RE, Dunbar CE. Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. Hum Gene Ther. 2001;12(6): 607-617.
47. Kuramoto K, Follman D, Hematti P, et al. The impact of low-dose busulfan on clonal dynamics in nonhuman primates. Blood. 2004;104(5): 1273-1280.
48. Soci'e G, Salooja N, Cohen A, et al Late Effects Working Party of the European Study Group for Blood and Marrow Transplantation. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101(9):3373- 3385.
49. Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfancyclophosphamide conditioning. Blood. 2011; 117(1):316-322.